1. Afatinib (2012) Food and Drug Administration. Center for Drug Evaluation and Research. Clinical Pharmacology and Biopharmaceutics Review(s). Available at: www.accessdata.fda.gov/drugsatfda_docs/nda/2013 /201292Orig1s000ClinPharmR.pdf (Accessed 10 March 2023)
2. Alectinib (2016) Committee for Medicinal Products for Human Use. European Medicines Agency. Alecensa. European public assessment report. Available at: www.ema.europa.eu/en/documents/assessment-report /alecensa-epar-public-assessment-report_en.pdf (Accessed 11 March 2023)
3. Role of Tyrosine Kinase Inhibitors in Cancer Therapy
4. Brigatinib (2017) Food and Drug Administration. Center for Drug Evaluation and Research. NDA Multidisciplinary Review and Evaluation NDA 208772 ALUNBRIG (brigatinib). Available at: www.accessdata.fda.gov /drugsatfda_docs/nda/2017/208772Orig1s000MultidisciplineR.pdf (Accessed 10 March 2023)
5. Population pharmacokinetics and exposure-response of osimertinib in patients with non-small cell lung cancer